ReviewPancreas2013
Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.
Review in Pancreas, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Impact of exosome therapy on pancreatic cancer and its progression.Medical oncology (Northwood, London, England) · 2023Review
- Article
- miRSCAPE - inferring miRNA expression from scRNA-seq data.iScience · 2022Article
- Research progress on microRNAs as molecular markers in pancreatic cancer: a narrative review.Journal of gastrointestinal oncology · 2022Review
- Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer.Translational oncology · 2021Review
- Review
- Advances in pancreatic cancer biomarkers.Oncology reviews · 2019Article
- Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells.Oncotarget · 2018Article
- Study of miR-143 expression in stomach cancer.Oncology letters · 2018Article
- MicroRNAs in pancreatic cancer diagnosis and therapy.Central-European journal of immunology · 2018Review
- Identification of potential key genes associated with glioblastoma based on the gene expression profile.Oncology letters · 2017Article
- Disorders noticed during development of pancreatic cancer: potential opportunities for early and effective diagnostics and therapy.Central-European journal of immunology · 2017Review
- MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.World journal of gastrointestinal oncology · 2016Review
- Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness.Neuro-oncology · 2015Article
- The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.Pancreas · 2015Review
- Interaction of Serum microRNAs and Serum Folate With the Susceptibility to Pancreatic Cancer.Pancreas · 2015Article
- Novel therapeutic targets for pancreatic cancer.World journal of gastroenterology · 2014Review
- Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.BioMed research international · 2014Review
- Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
MicroRNAs (miRNAs) are 18- to 22-nucleotide-long, single-stranded, noncoding RNAs that regulate important biological processes including differentiation, proliferation, and response to cellular stressors such as hypoxia, nutrient depletion, and traversion of the cell cycle by controlling protein expression within the cell. Many investigators have profiled cancer tissue and serum miRNAs to identify potential therapeutic targets, understand the pathways involved in tumorigenesis, and identify diagnostic tumor signatures. In the setting of pancreatic cancer, obtaining pancreatic tissue is invasive and impractical for early diagnosis. Several groups have profiled miRNAs that are present in the blood as a means to diagnose tumor progression and predict prognosis/survival or drug resistance. Several miRNA signatures found in pancreatic tissue and the peripheral blood, as well as the pathways that are associated with pancreatic cancer, are reviewed here in detail. Three miRNA biomarkers (miR-21, miR-155, and miR-200) have been repetitively identified in both pancreatic cancer tissue and patients' blood. Those miRNAs regulate and are regulated by the central genetic and epigenetic changes observed in pancreatic cancer including p53, transforming growth factor β, p16(INK4A), BRCA1/2, and Kras. These miRNAs are involved in DNA repair, cell cycle, and cell invasion and also play important roles in promoting metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.